AKT in cancer: new molecular insights and advances in drug development.

@article{Mundi2016AKTIC,
  title={AKT in cancer: new molecular insights and advances in drug development.},
  author={Prabhjot S Mundi and Jasgit C. Sachdev and Carolyn Kay McCourt and Kevin Kalinsky},
  journal={British journal of clinical pharmacology},
  year={2016},
  volume={82 4},
  pages={943-56}
}
The phosphatidylinositol-3 kinase (PI3K)-AKT pathway is one of the most commonly dysregulated pathways in all of cancer, with somatic mutations, copy number alterations, aberrant epigenetic regulation and increased expression in a number of cancers. The carefully maintained homeostatic balance of cell division and growth on one hand, and programmed cell death on the other, is universally disturbed in tumorigenesis, and downstream effectors of the PI3K-AKT pathway play an important role in this… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS